R13 (drug)

R13
Clinical data
Other names	R-13; BrAD-R13; BrADR13; Braegen-01; Braegen01; 4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)
Routes of; administration	Oral
Drug class	TrkB agonist
ATC code	None;
Pharmacokinetic data
Metabolites	Tropoflavin
Identifiers
	IUPAC name [8-(methylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N-methylcarbamate;
CAS Number	1609067-49-3 ;
PubChem CID	90117609;
UNII	OGG19T0LU2;
Chemical and physical data
Formula	C19H16N2O6
Molar mass	368.345 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)NC;
	InChI InChI=1S/C19H16N2O6/c1-20-18(23)26-14-9-8-12-13(22)10-15(11-6-4-3-5-7-11)25-16(12)17(14)27-19(24)21-2/h3-10H,1-2H3,(H,20,23)(H,21,24); Key:NWWRHMSYZTWUBD-UHFFFAOYSA-N;

R13, also known as BrAD-R13 or as Braegen-01, is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB), the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF), which is under development for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and schizophrenia. It is taken orally.

The drug is a structural modification and prodrug of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin) with improved potency and pharmacokinetics, namely oral bioavailability and duration. The compound is a replacement for the earlier tropoflavin prodrug R7 and has similar properties to it. It was developed because while R7 displayed a good drug profile in animal studies, it showed almost no conversion into tropoflavin in human liver microsomes. In contrast to R7, R13 is readily hydrolyzed into tropoflavin in human liver microsomes.

R13, under the synonym and developmental code name BrAD-R13, is being developed by Braegen Pharmaceutical in China. As of August 2025, it is in phase 1 clinical trials for Alzheimer's disease and the preclinical research stage of development for all other indications.